Press release
Lipid-Nanoparticle Based Genomic Medicines Market Report- Expansive Coverage on the Profit Sources
According to the latest research by InsightAce Analytic, the Global Lipid-Nanoparticle Based Genomic Medicines Market Size is valued at USD 2.58 Bn in 2024 and is predicted to reach USD 38.04 Bn by the year 2034 at a 31.0% CAGR during the forecast period for 2025-2034.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/2380
Lipid nanoparticle (LNP)-based genomic therapies represent a cutting-edge advancement in the field of drug and gene delivery. These technologies leverage LNPs as efficient carriers for delivering nucleic acids-such as RNA (including messenger RNA or mRNA) and DNA-directly into cells to address genetic disorders at the molecular level. This delivery system has received significant attention, particularly for its critical role in the rapid development and deployment of mRNA vaccines during the COVID-19 pandemic. However, the potential applications of LNP-based therapies extend far beyond vaccines, positioning LNPs as a transformative platform in modern medicine.
LNPs have recently emerged as a foundational technology within the biopharmaceutical sector. It is estimated that more than two billion individuals globally have received COVID-19 mRNA vaccines or boosters utilizing LNP delivery systems. Although this represents the most extensive application of LNPs in a clinical context to date, the technology itself has been under investigation for several decades, particularly for its potential in delivering genetic materials safely and effectively.
List of Prominent Players in the Lipid-Nanoparticle-Based Genomic Medicines Market:
• Moderna Inc.
• Pfizer Inc.
• BioNTech SE
• Arbutus Biopharma Corporation
• Arrowhead Pharmaceuticals Inc.
• CureVac N.V.
• Lipocalyx
• Acuitas Therapeutics
• Precision NanoSystems Inc.
• IONTAS Limited
• Genevant Sciences
• Roche Holding AG
• Alnylam Pharmaceuticals Inc.
• SiO2 Materials Science
• Ethris GmbH
• BIOVECTRA
• Avanti Polar Lipids, Inc. (Croda International Plc.),
• Recipharm AB
• eTheRNA
• ST Pharm Co Ltd,
• Others
Market Dynamics: -
Drivers-
Advancements in nanotechnology, particularly in lipid-based nanoparticles (LNPs), are a major driving force behind the growth of lipid nanoparticle-based genomic therapeutics. These innovations have significantly enhanced the precision and effectiveness of drug delivery systems, thereby improving the therapeutic performance of genetic treatments. Another critical growth factor is the rapid expansion of genomic medicines-especially mRNA-based therapeutics-targeting a wide array of diseases, including genetic disorders, cancer, and infectious diseases. This rising adoption has amplified the demand for robust and efficient LNP-based delivery platforms.
Curious About This Latest Version Of The Report? Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/2380
Challenges-
Despite promising advancements, the market faces several hurdles. Stringent regulatory frameworks and uncertainty in approval pathways may delay or restrict access to LNP-based genetic therapies. Unexpected adverse effects can erode trust among healthcare professionals, regulatory authorities, and patients, further challenging market penetration.
Regional Trends:
North America leads the global market for lipid nanoparticle-based genomic medicines, largely due to its advanced healthcare infrastructure and strong presence of major pharmaceutical and biotechnology companies. Institutions such as the National Institutes of Health (NIH) play a pivotal role by supporting innovation through substantial R&D investments.
The region's emphasis on cutting-edge development has resulted in significant progress in gene therapy and mRNA-based treatments utilizing LNP technologies. Furthermore, the high prevalence of chronic diseases in North America underscores the demand for advanced drug delivery systems, including LNPs. Most of the global LNP manufacturing and service providers are headquartered in North America, followed closely by Europe.
Recent Development-
• In August 2023, Avanti Polar Lipids and Bioz teamed together to find pertinent product and method knowledge to support effective research and development of innovative lipid-based products.
• In July 2023, McGill University entered into a partnership with ModernaTX to evaluate the characteristics (including size and payload distribution) of LNPs; the outcome of the project is likely to support in the optimization of LNP manufacturing process and serve as a quality check during the manufacturing of mRNA-based therapeutics.
Get Specific Chapter/Information From The Report: @ https://www.insightaceanalytic.com/customisation/2380
Segmentation of Lipid-Nanoparticle-Based Genomic Medicines Market-
By Type-
• Liposome-based Nanoparticles
• Micelle-based Nanoparticles
• Lipid-Coated Nanoparticles
By Application-
• Cancer Treatment
• Infectious Diseases
• Genetic Disorders
• Cardiovascular Diseases
• Others
By Therapeutic Payload-
• mRNA-based Therapeutics
• siRNA-based Therapeutics
• miRNA-based Therapeutics
• Other Genomic Medicines
By End-User-
• Hospitals
• Biopharmaceutical Companies
• Research Institutes
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Get More Information :
https://www.insightaceanalytic.com/report/lipid-nanoparticle-based-genomic-medicines-market/2380
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lipid-Nanoparticle Based Genomic Medicines Market Report- Expansive Coverage on the Profit Sources here
News-ID: 4162013 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
CO2 Medical Laser Systems Market Exclusive Report on the Latest Revenue and Futu …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global CO2 Medical Laser Systems Market Size, Share & Trends Analysis Report By Application (Urology, Ophthalmology, Dermatology, Gynecology, Veterinary, Dentistry, ENT, Cardiovascular and Others), End User (Outpatient Facilities, Hospitals and Research & Manufacturing), Distribution Channel (Online and Offline), Region, Market Outlook And Industry Analysis 2031"
The global CO2 medical laser systems market is estimated to reach over…
Coconut Shell Powder Market Report Latest Trends and Future Opportunities Analys …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Coconut Shell Powder Market Size, Share & Trends Analysis Report By Mesh Size (80-100 Mesh, 200-300 Mesh), by Application (Insect Repellent, Activated Carbon, Extender and Filler, Absorbent, Others), by Sales Channel (Offline, Online)- Market Outlook And Industry Analysis 2034"
The coconut shell powder market is estimated to reach over USD 675.1 Mn by 2034, exhibiting a…
Deep Venous Disease Treatment Devices Market Current Scenario with Future Aspect …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global xx Market Size, Share & Trends Analysis Report By products (Thrombectomy and Thrombolysis Devices, Inferior Vena Cava (IVC) Filters, Peripheral Vascular Stents, PTA Balloon Catheters, Accessory Devices, and Compression Devices/Stockings) and End-user (Hospitals and Clinics, Ambulatory Surgical Centers, and Homecare)- Market Outlook And Industry Analysis 2031"
The Global Deep Venous Disease Treatment Market is estimated…
Digital Insomnia Therapeutics Market Growth and Restrain Factors Analysis Report
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Digital Insomnia Therapeutics Market Size, Share & Trends Analysis Report By Type (Sleep Tracking Apps. Relaxation and Meditation Apps, CBT-I, Wearable Devices), Distribution Channel (Mobile App Stores, Healthcare Providers and Clinics, and Other Distribution Channels) , Region, Market Outlook And Industry Analysis 2031"
The global Digital Insomnia Therapeutics market is estimated to reach over USD 5.16…
More Releases for LNP
Lipid Nanoparticles (LNP) Market Outlook and Future Projections for 2030
The lipid nanoparticles (lnp) market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
LNP-based Therapies: A Look at the High-Growth LNP CDMO Market Fueling Innovatio …
The Lipid Nanoparticles (LNPs) CDMO Market to reach over USD 518.2 Mn by the year 2031 - Exclusive Report by Insight Ace Analytic
"The Lipid Nanoparticles (LNPs) CDMO Market" in terms of revenue was estimated to be worth $182.0 Mn in 2023 and is poised to reach $518.2 Mn by 2031, growing at a CAGR of 14.10% from 2024 to 2031 according to a new report by Insight Ace Analytic.
Get…
CD Bioparticles Announces Comprehensive Assay Portfolio for mRNA-LNP Vaccine Dev …
CD Bioparticles is pleased to announce a suite of mRNA-LNP Vaccine Laboratory Process Development Assays.
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is pleased to announce a suite of comprehensive mRNA-LNP Vaccine [https://www.cd-bioparticles.net/services/bioparticles-analysiscand-characterization/mrna-lnp-vaccine-laboratory-process-development-assay] Laboratory Process Development Assays. This latest addition to CD Bioparticles' extensive service portfolio is specifically designed for the rapid and efficient development of mRNA-LNP vaccines.
The mRNA molecule is well known to…
Lipid Nanoparticles (LNP) Market Growth Is Attributed To The Increasing Demand F …
According to Precision Business Insights (PBI) latest report, the Lipid Nanoparticles (LNP) Market size is expected to be worth USD 675.0 Million in 2022, growing at a 7.5% CAGR from 2022 to 2028. The growing demand for therapeutic drugs and vaccinations to combat viral illnesses like Ebola, influenza, HIV, and other viruses, together with the traditional vaccine approach's failure to find vaccines in time for a crisis, are all contributing…
SABIC’s new LNP™ ELCRES™ EXL resin delivers superior flame retardance
The implementation of the International Electrotechnical Commission’s new IEC 62368-1 safety standard for consumer electronics is prompting many manufacturers to seek higher-performing flame-retardant (FR) materials. Realme, a leading Chinese smartphone manufacturer, has selected SABIC’s new LNP™ ELCRES™ EXL7414 copolymer resin for the battery enclosure of its C25 phone to achieve UL 94 V0 FR compliance at 0.6mm, addressing the new IEC standard. Additionally, the superior flame retardance of the new…
SABIC HOSTS FIRST EUROPEAN LNP™ ANNIVERSARY TECHNICAL SUMMIT
BERGEN OP ZOOM, THE NETHERLANDS, June 11, 2019 - SABIC is holding a series of technical summits around the world to mark 70 years of its LNP™ product line of engineering thermoplastic compounds and copolymers. Following a series of events in Asia that began late last year, SABIC has initiated a schedule of events in cities across Europe and the USA.
The European leg began in mid-May at SABIC’s facilities in…
